← Alle Unternehmen
Über das Unternehmen
Ninsun Biotech provides the first clinically validated test that specifically measures cancer stem cells (CSCs) to reveal the true aggressiveness of lung tumors and predict immunotherapy failure before treatment even starts. While imaging only shows tumor size, our CE-marked test quantifies CSC-driven immune escape from a single biopsy, fitting seamlessly into routine pathology workflows. We already validated prognosis on over 300 patients with leading cancer centers and are now unlocking predictive immunotherapy response with the same assay. Our technology enables oncologists to avoid ineffective therapies, improve survival and reduce costs. Ninsun Biotech is redefining precision oncology by staying ahead of cancer, from day one.